Try our beta test site

Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Oslo University Hospital
Information provided by (Responsible Party):
Mona-Elisabeth Revheim, Oslo University Hospital Identifier:
First received: January 12, 2011
Last updated: January 22, 2016
Last verified: January 2016
The purpose of this study is to compare sensitivity, specificity and accuracy of PET, DW MRI and CT separately and combined for the evaluation of treatment response and progression-free survival in patients with GIST.

Soft Tissue Neoplasms
Gastrointestinal Tract

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Radiologic-pathologic correlation [ Time Frame: 2 years ]

Estimated Enrollment: 40
Study Start Date: February 2011
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
GIST patients suitable for medical treatment with targeted therapies.

Inclusion Criteria:

  • Metastatic GIST patients suitable for TKI treatment
  • GIST patients pursuing preoperative neoadjuvant TKI treatment

Exclusion Criteria:

  • Patients with contraindications to MRI and/or TKI treatment. For patients with renal failure, CT without intravenous contrast will be performed according to clinical practice.
  • Patients who do not sign the consent paper for any reason or do not accept the study premises or patients who wish to withdraw for any reason during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01276483

Contact: Mona-Elisabeth Revheim, MD +4723070840
Contact: Therese Seierstad, PhD +4722781237

Oslo University Hosptal Recruiting
Oslo, Norway, 0424
Principal Investigator: Mona-Elisabeth Revheim, MD         
Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Mona-Elisabeth Revheim, MD Oslo University Hospital, Dept of Nuclear Medicine
Study Chair: Therese Seierstad, PhD Oslo University Hospital, Institute for Cancer Research
Principal Investigator: Øyvind S Bruland, Prof., MD Oslo University Hospital, Dept of Oncology, The Norwegian Radium Hospital
Principal Investigator: Knut Håkon Hole, MD Oslo University Hospital, Department of Diagnostic Radiology
Principal Investigator: Lars Julsrud, MD Oslo University Hospital, Department of Diagnostic Radiology
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mona-Elisabeth Revheim, Nuclear Medicine Phycisian, Oslo University Hospital Identifier: NCT01276483     History of Changes
Other Study ID Numbers: REK-2010/2089
Study First Received: January 12, 2011
Last Updated: January 22, 2016

Keywords provided by Oslo University Hospital:
Response Monitoring
Functional Magnetic Imaging
Positron Emission Tomography
Computer Tomography

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Soft Tissue Neoplasms
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Neoplasms by Site processed this record on March 28, 2017